Nebula Research & Development LLC Lowers Position in Cencora, Inc. (NYSE:COR)

Nebula Research & Development LLC decreased its stake in Cencora, Inc. (NYSE:COR - Free Report) by 83.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,592 shares of the company's stock after selling 8,182 shares during the quarter. Nebula Research & Development LLC's holdings in Cencora were worth $358,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. JFS Wealth Advisors LLC lifted its holdings in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after buying an additional 46 shares during the period. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the 4th quarter valued at about $30,000. Kentucky Trust Co acquired a new position in Cencora during the fourth quarter worth $33,000. Householder Group Estate & Retirement Specialist LLC lifted its holdings in Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Finally, WASHINGTON TRUST Co boosted its holdings in shares of Cencora by 37.7% during the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock worth $38,000 after acquiring an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors.

Cencora Stock Performance

Shares of NYSE COR traded up $1.38 during midday trading on Tuesday, hitting $293.35. 211,764 shares of the stock traded hands, compared to its average volume of 1,503,067. Cencora, Inc. has a one year low of $214.77 and a one year high of $296.65. The firm has a 50-day moving average of $273.47 and a two-hundred day moving average of $252.02. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market capitalization of $56.88 billion, a P/E ratio of 41.73, a PEG ratio of 1.31 and a beta of 0.60.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.75%. Cencora's dividend payout ratio (DPR) is 31.29%.

Insiders Place Their Bets

In other news, EVP Silvana Battaglia sold 5,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Steven H. Collis sold 14,579 shares of Cencora stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at approximately $89,027,442.53. This represents a 4.41 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,223 shares of company stock valued at $13,580,967. Insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on COR shares. Wells Fargo & Company boosted their price objective on shares of Cencora from $251.00 to $274.00 and gave the company an "equal weight" rating in a research report on Friday, March 14th. UBS Group raised their price objective on Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. StockNews.com raised shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Evercore ISI raised their target price on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $290.00.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.